Biotech Lab 4.0
Vaccine development by design
A revolutionary way to accelerate, control and implement processes in real time by creating intelligent networks of equipment and open data systems that govern each other.
AchilleS Vaccines Biotech Lab 4.0 is a new model of early stage development for new biopharmaceutical products, particularly those containing, or consisting of, recombinant proteins (e.g. vaccines, immuno-therapeutics, ), and a new model of pre-clinical R&D.
AchilleS Vaccines exploits integrated technological platforms to identify, select and develop future approaches to deliver effective products.
They Talk About Us
EU Malaria Fund: AchilleS Vaccines, Magnetrap, KELTIC Pharma and Sumaya receive a total of EUR 17.6 million to develop malaria vaccines, diagnostics and therapeutics.
Berlin, September 3, 2021 This week, AchilleS Vaccines S.r.l., Magnetrap SA, KELTIC Pharma Therapeutics Ltd and Sumaya Biotech GmbH & Co. KG. concluded contracts with the
Toscana Life Sciences Sviluppo annuncia la fase II/III di sperimentazione clinica per l’anticorpo monoclonale anti Covid-19
I test clinici coinvolgeranno oltre 800 pazienti con infezione da Coronavirus SARS-CoV-2 in 14 centri sperimentali del Paese Siena, 21 maggio 2021 – Prosegue con